These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 33965062)

  • 41. The age profile of respiratory syncytial virus burden in preschool children of low- and middle-income countries: A semi-parametric, meta-regression approach.
    Antillón M; Li X; Willem L; Bilcke J; ; Jit M; Beutels P
    PLoS Med; 2023 Jul; 20(7):e1004250. PubMed ID: 37459352
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Risk factors for acute respiratory syncytial virus infection of lower respiratory tract in hospitalized infants].
    Zhang X; Liu L; Shi P; Jiang G; Jia P; Wang C; Wang L; Qian L
    Zhonghua Er Ke Za Zhi; 2014 May; 52(5):373-7. PubMed ID: 24969937
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
    Régnier SA
    Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vaccine Induced Herd Immunity for Control of Respiratory Syncytial Virus Disease in a Low-Income Country Setting.
    Kinyanjui TM; House TA; Kiti MC; Cane PA; Nokes DJ; Medley GF
    PLoS One; 2015; 10(9):e0138018. PubMed ID: 26390032
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy.
    Scheltema NM; Kavelaars XM; Thorburn K; Hennus MP; van Woensel JB; van der Ent CK; Borghans JAM; Bont LJ; Drylewicz J
    Vaccine; 2018 Jul; 36(31):4693-4700. PubMed ID: 29941327
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands.
    Meijboom MJ; Rozenbaum MH; Benedictus A; Luytjes W; Kneyber MC; Wilschut JC; Hak E; Postma MJ
    Vaccine; 2012 Jun; 30(31):4691-700. PubMed ID: 22561315
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England.
    Cromer D; van Hoek AJ; Newall AT; Pollard AJ; Jit M
    Lancet Public Health; 2017 Aug; 2(8):e367-e374. PubMed ID: 28804787
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Meeting report: WHO consultation on Respiratory Syncytial Virus (RSV) vaccine development, Geneva, 25-26 April 2016.
    Giersing BK; Karron RA; Vekemans J; Kaslow DC; Moorthy VS
    Vaccine; 2019 Nov; 37(50):7355-7362. PubMed ID: 28302410
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis.
    Hodgson D; Pebody R; Panovska-Griffiths J; Baguelin M; Atkins KE
    BMC Med; 2020 Nov; 18(1):348. PubMed ID: 33203423
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis.
    Cong B; Koç U; Bandeira T; Bassat Q; Bont L; Chakhunashvili G; Cohen C; Desnoyers C; Hammitt LL; Heikkinen T; Huang QS; Markić J; Mira-Iglesias A; Moyes J; Nokes DJ; Ploin D; ; Seo E; Singleton R; Wolter N; Fu Yung C; Zar HJ; Feikin DR; Sparrow EG; ; Nair H; Li Y;
    Lancet Infect Dis; 2024 Apr; 24(4):361-374. PubMed ID: 38141633
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi District, Kenya.
    Nokes DJ; Okiro EA; Ngama M; Ochola R; White LJ; Scott PD; English M; Cane PA; Medley GF
    Clin Infect Dis; 2008 Jan; 46(1):50-7. PubMed ID: 18171213
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions.
    Laufer RS; Driscoll AJ; Baral R; Buchwald AG; Campbell JD; Coulibaly F; Diallo F; Doumbia M; Galvani AP; Haidara FC; Kotloff KL; Keita AM; Neuzil KM; Orenstein EW; Orenstein LAV; Pecenka C; Sow S; Tapia MD; Ortiz JR; Fitzpatrick MC
    Vaccine; 2021 Aug; 39(35):5037-5045. PubMed ID: 34325934
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost of hospitalization for respiratory syncytial virus chest infection and implications for passive immunization strategies in a developing nation.
    Chan PW; Abdel-Latif ME
    Acta Paediatr; 2003 Apr; 92(4):481-5. PubMed ID: 12801117
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series.
    Scheltema NM; Gentile A; Lucion F; Nokes DJ; Munywoki PK; Madhi SA; Groome MJ; Cohen C; Moyes J; Thorburn K; Thamthitiwat S; Oshitani H; Lupisan SP; Gordon A; Sánchez JF; O'Brien KL; ; Gessner BD; Sutanto A; Mejias A; Ramilo O; Khuri-Bulos N; Halasa N; de-Paris F; Pires MR; Spaeder MC; Paes BA; Simões EAF; Leung TF; da Costa Oliveira MT; de Freitas Lázaro Emediato CC; Bassat Q; Butt W; Chi H; Aamir UB; Ali A; Lucero MG; Fasce RA; Lopez O; Rath BA; Polack FP; Papenburg J; Roglić S; Ito H; Goka EA; Grobbee DE; Nair H; Bont LJ
    Lancet Glob Health; 2017 Oct; 5(10):e984-e991. PubMed ID: 28911764
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children.
    Nair H; Verma VR; Theodoratou E; Zgaga L; Huda T; Simões EA; Wright PF; Rudan I; Campbell H
    BMC Public Health; 2011 Apr; 11 Suppl 3(Suppl 3):S30. PubMed ID: 21501449
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunoglobulin for preventing respiratory syncytial virus infection.
    Wang EE; Tang NK
    Cochrane Database Syst Rev; 2000; (2):CD001725. PubMed ID: 10796658
    [TBL] [Abstract][Full Text] [Related]  

  • 57. What U.S. Obstetricians Need to Know About Respiratory Syncytial Virus.
    Debessai H; Jones JM; Meaney-Delman D; Rasmussen SA
    Obstet Gynecol; 2024 Mar; 143(3):e54-e62. PubMed ID: 38061043
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Value profile for respiratory syncytial virus vaccines and monoclonal antibodies.
    Fleming JA; Baral R; Higgins D; Khan S; Kochar S; Li Y; Ortiz JR; Cherian T; Feikin D; Jit M; Karron RA; Limaye RJ; Marshall C; Munywoki PK; Nair H; Newhouse LC; Nyawanda BO; Pecenka C; Regan K; Srikantiah P; Wittenauer R; Zar HJ; Sparrow E
    Vaccine; 2023 Nov; 41 Suppl 2():S7-S40. PubMed ID: 37422378
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
    Munoz FM
    Curr Opin Infect Dis; 2015 Jun; 28(3):221-4. PubMed ID: 25918956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.